Anti-C4.4A/LYPD3 antibody

单克隆

兔

兔IgG

Rabbit monoclonal to C4.4A/LYPD3

FCM

FCM

Human C4.4A / LYPD3

C4.4A, C4.4a, 2310061G07Rik, C4.4a, LYPD3, UNQ491/PRO1007, 2310061G07Rik, C4.4A, Lypd3

This antibody was obtained from a rabbit immunized with purified, recombinant Human C4.4A / LYPD3 (rh C4.4A / LYPD3; NP_055215.2; Met1-His286) and conjugated with PE under optimum conditions, the unreacted PE was removed.

Aqueous solution containing 0.5% BSA and 0.09% sodium azide

This antibody is stable for 12 months from date of receipt when stored at 2℃-8℃. Protected from prolonged exposure to light. Do not freeze !
Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.

Ly6 / PLAUR domain-containing protein 3, also known as GPI-anchored metastasis-associated protein C4.4A homolog, Matrigel-induced gene C4 protein, MIG-C4 and LYPD3, is a cell membrane protein which contains two UPAR/Ly6 domains. Human LYPD3 contains two UPAR/Ly6 domains. LYPD3 is expressed in placenta, skin and urothelium. It is found in suprabasal keratinocytes of chronic wounds. Weak expression of LYPD3 is found in esophagus and peripheral blood mononuclear cells. It is found in the majority of primary and metastatic transitional cell carcinomas (TCCs) and as well in breast cancer tissues, but not in adjacent normal tissues. High expression of LYPD3 is found in the tumor component of some noninvasive superficial lesions and in invasive and metastatic urothelial cancers. LYPD3 is up-regulated in migrating keratinocytes during epithelisation of incisional skin wounds. LYPD3 supports cell migration. It may be involved in urothelial cell-matrix interactions. It may also be involved in tumor progression

• Smith B.A., et al., 2001, Cancer Res. 61:1678-85.
• Wuerfel J., et al., 2001, Gene 262:35-41.
• Clark H.F., et al., 2003, Genome Res. 13:2265-70.
• Fletcher G.C., et al., 2003, Br. J. Cancer 88:579-85.
• Hansen L.V., et al., 2004, Biochem. Eng. J. 380:845-57.